FDA Recalls PharmaTech Liquid Products for B. cepacia Contamination Risk
On August 10, 2017, FDA announced a voluntary recall of all liquid products manufactured by PharmaTech and distributed by Leader Brand, Major Pharmaceuticals and Rugby Laboratories because of possible Burkholderia cepacia (B. cepacia) contamination.
On August 10, 2017, FDA announced a voluntary recall of all liquid products manufactured by PharmaTech and distributed by Leader Brand, Major Pharmaceuticals and Rugby Laboratories because of possible Burkholderia cepacia (B. cepacia) contamination. The recalled products were distributed nationwide at wholesale and retail facilities including hospitals and pharmacies.
These products, which include various drugs and dietary supplements intended for use in infants and children, have been linked to a PharmaTech-manufactured product connected to severe adverse event reports of B. cepacia infections in patients. After being alerted to the issue by FDA, Rugby Laboratories issued a voluntary recall on August 3, 2017 of Diocto Syrup and Diocto Liquid (docusate sodium solutions). As a precautionary measure based on additional information received from FDA, the three distribution firms are recalling all lots within expiry of all liquid products manufactured by the manufacturing company. The distribution firms have sent out recall letters and arranged for the return of all recalled products.
Consumers, pharmacies, and healthcare facilities that have the recalled product should cease use and report any adverse events.
Source: FDA
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
